Minimum Dose CT Post Lung Biopsy
Phase 1
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT00188162
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
The aim is to evaluate whether Minimum Dose CT (MnDCT) is useful in the management of patients post Lung Biopsy
- Detailed Description
Patients post Lung Biopsy have a chest X-ray (CXR) and a MnDCT post lung biopsy. Both studies are compared for the detection of a pneumothorax
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- All Patients having a lung biopsy
Exclusion Criteria
- None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Detection of Pneumothorax
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pneumothorax detection by MnDCT after lung biopsy in lung cancer patients?
How does Minimum Dose CT compare to standard chest X-ray in detecting post-biopsy complications in non-small cell lung cancer?
Are there specific biomarkers that correlate with pneumothorax risk following lung biopsy requiring MnDCT monitoring?
What adverse events are associated with MnDCT imaging in lung cancer patients post-biopsy compared to conventional CT scans?
How do low-dose CT protocols in NCT00188162 influence radiation exposure and clinical outcomes in lung cancer patients?
Trial Locations
- Locations (1)
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Toronto General Hospital🇨🇦Toronto, Ontario, Canada